SCYNEXIS Receives FDA Qualified Infectious Disease Product (QIDP) and Fast Track Designations for SCY-247

SCYNEXIS (NASDAQ: SCYX) announced that the U.S. FDA granted QIDP and Fast Track designations for its second‑generation triterpenoid antifungal, SCY-247.

Rhea-AI Summary

SCYNEXIS (NASDAQ: SCYX) announced that the U.S. FDA granted QIDP and Fast Track designations for its second‑generation triterpenoid antifungal, SCY-247. The company noted QIDP will provide at least 10 years of post‑approval market exclusivity and Fast Track may enable more frequent FDA interaction, rolling review, and eligibility for accelerated approval or priority review. SCYNEXIS plans to initiate a Phase 1 IV study and a Phase 2 oral study in invasive candidiasis in 2026, and aims to release oral proof‑of‑concept data the same year. SCY-247 has shown preclinical activity against multi‑drug resistant fungi including Candida auris and azole‑resistant Aspergillus.

Positive

• QIDP designation for SCY-247 with at least 10 years exclusivity
• Fast Track designation enabling more frequent FDA interactions
• Plans to start Phase 1 IV and Phase 2 oral studies in 2026
• Phase 1 SAD/MAD data showed target exposures at lower doses
• Broad preclinical activity vs multi‑drug‑resistant Candida auris

Negative

• None.

Argus Jan 21 session

+4.01% close to close Open Argus

Details

News Market Reaction – SCYX

On Jan 21, the day this news came out, SCYX closed 4.01% above the previous close.

Data tracked by StockTitan Argus for the Jan 21 session.

Key Figures

Market exclusivity: 10 years Exclusivity extension: 5-year extension Phase 1 study: Phase 1 +2 more

Market exclusivity

10 years

QIDP designation market exclusivity after approval for SCY-247

Exclusivity extension

5-year extension

QIDP-approved drugs receive 5-year extension to qualifying exclusivity

Phase 1 study

Phase 1

Planned 2026 IV formulation study of SCY-247 in invasive candidiasis

Phase 2 study

Phase 2

Planned 2026 oral formulation study in invasive candidiasis

Proof-of-concept timing

2026

Target year for SCY-247 oral proof-of-concept data in invasive candidiasis

Historical Context

5 past events · Latest: Dec 22

5 events

1. Dec 22

   Nasdaq extension

   24h Move

   -2.3%

   Nasdaq grants bid-price compliance extension to June 15, 2026.

2. Nov 19

   NDA transfer

   24h Move

   +1.8%

   BREXAFEMME NDA transfer to GSK with up to $145.5M milestones.

3. Nov 17

   Federal funding

   24h Move

   -1.4%

   Collaboration in CETR with ~$7M annually for antifungal projects.

4. Nov 05

   Q3 earnings

   24h Move

   +0.1%

   Q3 results plus $24.8M GSK payment and >2-year cash runway.

5. Oct 15

   GSK resolution

   24h Move

   -0.3%

   Resolution of MARIO dispute with ~$24.3M total payments from GSK.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Key Terms

qualified infectious disease product, qidp, fast track, phase 1, +4 more

8 terms

qualified infectious disease product regulatory

"FDA has granted the Company Qualified Infectious Disease Product (QIDP)..."

A qualified infectious disease product is a drug or biologic given a special regulatory label because it targets serious or life‑threatening infections and meets public‑health needs. The label brings incentives such as faster regulatory review, development tax benefits, and extra time with market exclusivity—think of it as a VIP pass and an extended storefront lease that can speed approval and delay generic competition. For investors, that can raise a candidate’s commercial value, lower development risk and make partnerships or buyouts more likely.

qidp regulatory

"The QIDP designation will ensure at least 10 years of market exclusivity..."

A QIDP (Qualified Infectious Disease Product) is a regulatory designation for drugs or biologics that treat serious bacterial or fungal infections. It signals faster review and gives additional market protection after approval, like an extra patent-like time window, which can delay competitors — think of it as a temporary “no-competition” zone enforced by the regulator. For investors, QIDP status can speed a product to market and meaningfully enhance revenue potential and valuation.

fast track regulatory

"has granted the Company Qualified Infectious Disease Product (QIDP) and Fast Track Designations..."

A fast track designation is a regulatory label that speeds up the review and communication between a drug developer and regulators for treatments addressing serious illnesses or unmet medical needs. For investors, it matters because it can shorten development time and reduce regulatory delays—like getting a VIP lane at the airport—raising the chance of earlier market access and potential revenue, though it does not guarantee approval.

phase 1 medical

"expects to initiate a Phase 1 study of SCY-247 with the IV formulation..."

Phase 1 is the first stage of testing a new drug or medical treatment in people, focused primarily on safety, how the body handles the product, and finding a tolerated dose. Think of it as a short, tightly controlled experiment with a small group to check for dangerous side effects before wider testing; for investors it is an early milestone that reduces some uncertainty but still carries high risk and potential for both big value changes and setbacks.

phase 2 medical

"as well as a Phase 2 study with the oral formulation in invasive candidiasis..."

Phase 2 is the mid-stage clinical trial where a new drug or treatment is tested in a larger group of patients to see if it works and to keep checking safety after initial human testing. Think of it as a field test that proves whether a product actually delivers its promised benefit. Investors watch Phase 2 closely because its results strongly influence a medicine’s chances of reaching the market, the size of its potential sales, and the company’s valuation.

candida auris medical

"multi-drug resistant, Candida auris fungal infection..."

Candida auris is a species of yeast that can cause serious infections and is notable for often resisting multiple antifungal drugs; it spreads easily in healthcare settings and can persist on surfaces like a stubborn stain. For investors, it matters because outbreaks create demand for better diagnostics, new treatments, infection-control products and hospital services, and they can prompt regulatory action and costly containment efforts that affect healthcare and biotech companies.

biologic license application regulatory

"sections of its Biologic License Application (BLA) or New Drug Application (NDA)..."

A biologic license application is a formal regulatory submission seeking permission to market a biological medicine—such as a vaccine, antibody, or cell therapy—by showing evidence about safety, effectiveness, and consistent manufacturing. For investors it is a major milestone: approval is like a commercial “green light” that unlocks sales, exclusivity and potential revenue, while delays or rejection can push back earnings and reduce a company’s valuation.

new drug application regulatory

"Biologic License Application (BLA) or New Drug Application (NDA) for review by FDA..."

A new drug application is a formal request submitted to government regulators seeking approval to market a new medicine. It is like a detailed proposal that shows the drug has been tested for safety and effectiveness. For investors, receiving approval signals that the drug may soon become available for sale, potentially leading to revenue growth and impacting the company's value.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

The QIDP designation will ensure at least 10 years of market exclusivity for SCY-247 following approval

Recent articles highlight the growing threat from a rapidly spreading, multi-drug resistant, Candida auris fungal infection

JERSEY CITY, N.J., Jan. 21, 2026 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and drug-resistant infections, today announced that the U.S. Food and Drug Administration (“FDA”) has granted the Company Qualified Infectious Disease Product (QIDP) and Fast Track Designations for its second-generation triterpenoid antifungal therapy, SCY-247.

“Receiving FDA’s QIDP and Fast Track designations for SCY-247 reflects the potential of SCY-247 to address the serious unmet need posed by life-threatening resistant fungal infections,” said David Angulo, M.D., President and Chief Executive Officer of SCYNEXIS. “Last year we presented results from multiple preclinical efficacy models consistently showing the potent antifungal activity of SCY-247 against a broad array of fungal pathogens, including some of the most difficult to treat such as Candida auris and echinocandin-resistant C. glabrata, as well as data supporting extensive tissue distribution. We also disclosed positive Phase 1 SAD/MAD data that not only demonstrated SCY-247’s promising safety and favorable pharmacokinetic properties, but also showed that the drug could achieve target exposures for invasive fungal disease at doses lower than our first generation fungerp. The data generated to date strongly positions SCY-247 as a unique candidate to address the clear need for novel, safe and potent antifungal agents able to address the rising threat of antifungal resistance.”

In 2026, the Company expects to initiate a Phase 1 study of SCY-247 with the IV formulation as well as a Phase 2 study with the oral formulation in invasive candidiasis (IC). SCYNEXIS also aims to release proof-of -concept data for the oral formulation of SCY-247 in IC in 2026. Considering the differentiated attributes of SCY-247 and its potential role to counter health security threats posed by antifungal resistance development, we will also continue exploring potential non-dilutive funding opportunities to further support this program.

Scientific and media publications continue to highlight the need for novel antifungal solutions to address the growing public health threat resulting from the emergence of multi-drug resistant fungal pathogens such as Candida auris. In December 2025, a collaborative multi-institution scientific publication reported that Candida auris is spreading across the globe, and gaining in virulence (link to their article here). The Independent published an article this month highlighting the growing public health threat in the United States from a rapidly spreading “superbug” strain of Candida auris. The article notes how individuals with compromised immune systems are particularly vulnerable to this strain of fungal infection, which does not respond to currently approved antifungal therapies. A link to the article can be found here.

With its broad spectrum of activity, the Company believes that SCY-247 has the potential to address this growing public health threat, due to its demonstrated activity against most drug-resistant fungi, including multi-drug-resistant Candida auris and azole-resistant Aspergillus spp.

For a drug product to be designated a QIDP, the sponsor is required to demonstrate that the drug is an antibacterial or antifungal drug for human use intended to treat serious or life-threatening infections. Subject to the specified statutory limitations, a drug that is designated as a QIDP and is approved for the use for which the QIDP designation was granted will receive a 5-year extension to any exclusivity for which the application qualifies upon approval.¹

A drug that receives Fast Track designation is eligible for some or all of the following:²

• More frequent meetings with FDA to discuss the drug's development plan and ensure collection of appropriate data needed to support drug approval
• More frequent written communication from FDA about such things as the design of the proposed clinical trials and use of biomarkers
• Eligibility for Accelerated Approval and Priority Review, if relevant criteria are met
• Rolling Review, which means that a drug company can submit completed sections of its Biologic License Application (BLA) or New Drug Application (NDA) for review by FDA, rather than waiting until every section of the NDA is completed before the entire application can be reviewed. BLA or NDA review usually does not begin until the drug company has submitted the entire application to the FDA

About SCYNEXIS
SCYNEXIS, Inc. (NASDAQ: SCYX) is a biotechnology company pioneering innovative medicines to help millions of patients worldwide overcome and prevent difficult-to-treat infections that are becoming increasingly drug-resistant. SCYNEXIS is developing the company’s proprietary antifungal platform “fungerps.” Ibrexafungerp, the first representative of this novel class, has been licensed to GSK. The U.S. Food and Drug Administration (FDA) has approved BREXAFEMME^® (ibrexafungerp tablets) for the treatment of vulvovaginal candidiasis (VVC) and for reduction in the incidence of recurrent VVC. Additional antifungal assets from this novel class are currently in clinical, pre-clinical and discovery phases, including the compound SCY-247. For more information, visit www.scynexis.com.

Forward-Looking Statements

Statements contained in this press release regarding expected future events or results are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, including but not limited to statements regarding: The Company’s expectation to initiate a Phase 1 study of SCY-247 with the IV formulation as well as a Phase 2 study with the oral formulation in invasive candidiasis (IC), the Company’s aim to release proof-of-concept data for the oral formulation of SCY-247 in IC in 2026, and the potential for SCY-247 to address fungal threats. Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. These risks and uncertainties include, but are not limited to, risks inherent in regulatory and other costs in developing products. These and other risks are described more fully in SCYNEXIS' filings with the Securities and Exchange Commission, including without limitation, its most recent Annual Report on Form 10-K filed on March 12, 2025, including under the caption "Risk Factors." All forward-looking statements contained in this press release speak only as of the date on which they were made. SCYNEXIS undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made.

CONTACT: 
Investor Relations
Irina Koffler
LifeSci Advisors
Tel: 917-734-7387
ikoffler@lifesciadvisors.com

¹ Source: https://www.fda.gov/media/148480/download 
² Source: https://www.fda.gov/patients/fast-track-breakthrough-therapy-accelerated-approval-priority-review/fast-track

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What does the FDA QIDP designation mean for SCYNEXIS (SCYX) SCY-247?

QIDP gives SCY-247 priority status and, per the announcement, at least 10 years of post‑approval market exclusivity.

How does Fast Track designation affect SCY-247's development timeline for SCYX?

Fast Track may allow more frequent FDA meetings, rolling review, and eligibility for accelerated approval or priority review to potentially speed review.

When will SCYNEXIS (SCYX) begin clinical studies for SCY-247?

The company expects to initiate a Phase 1 IV study and a Phase 2 oral study in invasive candidiasis in 2026.

What clinical data has SCYNEXIS reported for SCY-247 so far?

SCY-247 reported positive Phase 1 SAD/MAD safety and pharmacokinetic data showing target exposures at lower doses than the prior compound.

Does SCY-247 show activity against Candida auris for SCYX investors?

Preclinical results cited activity against multi‑drug‑resistant Candida auris and other resistant fungal pathogens.

When does SCYNEXIS expect proof‑of‑concept data for the oral SCY-247 (SCYX)?

The company aims to release oral proof‑of‑concept data in 2026.